ClinicalTrials.govrestricted
Phase 2 Study of PI3K Inhibitor Copanlisib in Combination With Fulvestrant in Selected ER+ and/or PR+ Cancers With PI3K (PIK3CA, PIK3R1) and/or PTEN Alterations
ClinicalTrials.gov study NCT05082025. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ShareScore
28/100
Overall dataset sharing score
Score breakdown
These five areas show where the dataset supports — or may limit — practical reuse.
- Stewardship
- 12
- Harmonization
- 8
- Access
- 4
- Reuse readiness
- 0
- Engagement
- 4